Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing Footage Emerges from MAPS Trial Post published:March 25, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine? Post published:March 18, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Tensions Rise Among Oregon’s Psilocybin Advisory Board; Colleges Team up to Develop Psychedelic Curriculum Post published:March 11, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead for Psychedelic Medicine Post published:March 7, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D? Post published:February 28, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in Depression; Cybin Partners with Chopra Foundation Post published:February 18, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Mindstate Design Labs Leaves Stealth Mode; No Synthetic Psilocybin in Oregon? Post published:February 14, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Patent Granted Covering DMT Vapes; Microdosing Produces “Negligible” Effects Post published:February 6, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MDMA Fast-Tracked in UK; FDA Clears MindMed LSD Trial; More Psychedelic Drug Policy Reform Efforts Emerge Post published:January 28, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: DEA Moves to Schedule 5 Tryptamines; Eleusis Unveils SPAC; COMPASS Seeks LSD Patents Post published:January 22, 2022 Post category:Psychedelic Bulletin